Latest news with #P3HealthPartners
Yahoo
29-05-2025
- Business
- Yahoo
P3 Health Partners price target lowered to $8 from $12.50 at TD Cowen
TD Cowen lowered the firm's price target on P3 Health Partners (PIII) to $8 from $12.50 and keeps a Hold rating on the shares. The firm updated its model to reflect Q1 results and adjusted its $o.50 target to reflect the company's 1-for-50 reverse stock split. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on PIII: Disclaimer & DisclosureReport an Issue P3 Health Partners' Earnings Call: Strategic Gains Amid Challenges P3 Health Partners: Positioned for Growth with Strategic Initiatives and Profitability Improvements P3 Health Partners Reports Q1 2025 Financial Results P3 Health Partners reports Q1 EPS ($6.28) vs ($7.86) last year P3 Health Partners backs FY25 revenue view $1.35B-$1.5B, consensus $1.41B Sign in to access your portfolio
Business Insider
28-05-2025
- Business
- Business Insider
TD Cowen Reaffirms Their Hold Rating on P3 Health Partners (PIII)
TD Cowen analyst Ryan Langston maintained a Hold rating on P3 Health Partners (PIII – Research Report) today and set a price target of $8.00. The company's shares closed today at $7.26. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Langston covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, P3 Health Partners, and UnitedHealth. According to TipRanks, Langston has an average return of -7.8% and a 27.78% success rate on recommended stocks. In addition to TD Cowen, P3 Health Partners also received a Hold from BTIG's David Larsen in a report issued on May 19. However, on May 16, William Blair maintained a Buy rating on P3 Health Partners (NASDAQ: PIII). The company has a one-year high of $33.70 and a one-year low of $7.00. Currently, P3 Health Partners has an average volume of 13.56K.
Associated Press
23-05-2025
- Business
- Associated Press
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ('Wolf Haldenstein'), a distinguished law firm with over 125 years of history, announces it is investigating claims on behalf of investors of P3 Health Partners, Inc. (NASDAQ: PIII) ('P3' or the 'Company'). (NASDAQ: PIII) Allegations and Investigation Focus: Triggering Events: 1. November 12, 2024 – P3 reported disappointing financial results in its Form 10-Q filed with the United States Securities and Exchange Commission (SEC): 2. March 28, 2025 – Annual Form 10-K disclosed: Why Wolf Haldenstein Adler Freeman & Herz LLP? This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors. We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP. Contact Information: Firm: Wolf Haldenstein Adler Freeman & Herz LLP Primary Contact: Gregory Stone, Director of Case and Financial Analysis Email: [email protected] or [email protected] Phone: (800) 575-0735 or (212) 545-4774 This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
